anthera...I always liked the lupus drug and thought it was a mistake to run trials on the cv Drug
I see they just had an interim look at the Phase 2b results ( http://investor.anthera.com/releasedetail.cfm?ReleaseID=654023 ) and they didn't get a halt for efficacy though trial was recommended to continue with top-line results expected in 2Q12. This is presumably a big binary event for them, given this failure and most of their other stuff looking very early stage.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.